ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 50,000 Shares

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 50,000 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the completion of the sale, the insider now owns 604,205 shares in the company, valued at approximately $8,579,711. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Jaume Pons also recently made the following trade(s):

• On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The stock was sold at an average price of $11.15, for a total value of $223,000.00.

ALX Oncology Trading Down 2.1 %

Shares of ALXO traded down $0.34 during mid-day trading on Thursday, reaching $15.74. 667,307 shares of the company’s stock traded hands, compared to its average volume of 434,640. ALX Oncology Holdings Inc. has a 12 month low of $3.94 and a 12 month high of $17.42. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The stock has a market cap of $789.36 million, a P/E ratio of -4.29 and a beta of 1.58. The stock’s 50-day moving average is $13.52 and its two-hundred day moving average is $11.87.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Research analysts forecast that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on ALXO shares. Stifel Nicolaus reissued a “hold” rating and issued a $14.00 target price (up from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Friday, April 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of ALX Oncology in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.83.

Hedge Funds Weigh In On ALX Oncology

Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of ALX Oncology in the fourth quarter valued at approximately $28,000. Royal Bank of Canada lifted its holdings in shares of ALX Oncology by 226.6% in the 2nd quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock worth $30,000 after buying an additional 2,776 shares during the period. Legal & General Group Plc grew its position in shares of ALX Oncology by 42.6% during the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock worth $34,000 after buying an additional 684 shares in the last quarter. UBS Group AG lifted its stake in ALX Oncology by 38.7% in the first quarter. UBS Group AG now owns 10,043 shares of the company’s stock worth $45,000 after acquiring an additional 2,801 shares during the period. Finally, SG Americas Securities LLC bought a new position in ALX Oncology during the 3rd quarter worth about $48,000. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.